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Commentary 
The Ryan White HIV/AIDS Program (RWHAP) is
administered by the U.S. Department of Health and 
Human Services (HHS), Health Resources and Ser-
vices Administration (HRSA), HIV/AIDS Bureau 
(HAB). The Ryan White Comprehensive AIDS
Resources Emergency (CARE) Act was passed by 
Congress in 1990 to address the crisis of the HIV epi-
demic in the United States. This legislation has been 
amended and reauthorized 4 times: in 1996, 2000,
2006, and most recently in 2009 as the Ryan White
HIV/AIDS Treatment Extension Act of 2009. More
information about the legislation and its history is
available from HRSA HAB at https://hab.hrsa.gov/ 
about-ryan-white-hivaids-program/. 
For the implementation of the RWHAP Metropoli-
tan (Part A) and State (Part B) programs, HRSA HAB
and the Centers for Disease Control and Prevention 
(CDC) collaborate to ensure the appropriate HIV and 
AIDS surveillance data are used in determining eligi-
bility and funding allocation amounts. In FY 2019,
HRSA used total counts of persons living with diag-
nosed HIV infection non-AIDS and persons living 
with infection ever classified as AIDS to calculate
funding allocation amounts for eligible jurisdictions.
For FY 2019, CDC provided HRSA with data files
containing this information through calendar year
2017 for all jurisdictions. The number of persons liv-
ing with diagnosed HIV infection non-AIDS and the
number of persons living with infection ever classified 
as AIDS were added together to arrive at the total num-
ber of persons living with diagnosed HIV infection 
non-AIDS and infection ever classified as AIDS for
each eligible area: eligible metropolitan area (EMA),
transitional grant area (TGA), emerging community 
(EC), state, and territory. These totals were used in the
RWHAP Parts A and B funding formula calculations.
RWHAP PART A FUNDING
For the RWHAP Part A funding formula, HRSA con-
tinues to use cumulative cases of AIDS reported to and 
confirmed by the Director of CDC for the most recent
5 calendar years for which such data are available to 
determine eligibility, as instructed by the RWHAP
statute. RWHAP Part A has 2 categories of grant recip-
ients for areas that have a minimum population of
50,000 persons: EMAs and TGAs. EMAs are defined 
as areas that have a cumulative total of more than 
2,000 AIDS cases reported to and confirmed by the
Director of CDC during the most recent 5 calendar
years for which such data are available. An area will
continue to be an EMA unless it fails to meet both of
the following requirements for 3 consecutive fiscal
years: (a) a cumulative total of more than 2,000 AIDS
cases reported to and confirmed by the Director of
CDC during the most recent period of 5 calendar years
for which such data are available, and (b) a cumulative
total of 3,000 or more persons living with HIV infec-
tion ever classified as AIDS reported to and confirmed 
by the Director of CDC as of December 31 of the most
recent calendar year for which such data are available.
In FY 2019, there were 24 EMAs. 
TGAs, the other category of Part A recipients, are
defined as areas that have a cumulative total of at least
1,000 but fewer than 2,000 AIDS cases reported to and 
confirmed by the Director of CDC during the most
recent 5 calendar years for which such data are avail-
able. An area will remain a TGA unless it fails to meet
both of the following requirements for 3 consecutive
fiscal years: (a) a cumulative total of at least 1,000 but
fewer than 2,000 cases of AIDS reported to and con-
firmed by the Director of CDC during the most recent
period of 5 calendar years for which such data are
available, and (b) a cumulative total of 1,500 or more
persons living with HIV infection ever classified as
AIDS reported to and confirmed by the Director of
CDC as of December 31 of the most recent calendar
year for which such data are available. Provisions in 
the RWHAP statute provided for a modification begin-
ning in FY 2009: in the case where a metropolitan area
has a cumulative total of at least 1,400 but fewer than 
1,500 persons living with HIV infection ever classified 
as AIDS as of December 31 of the most recent calen-
dar year for which such data are available, such area
shall be treated as having met criterion (b) as long as
the area did not have more than 5% unobligated bal-
ance as of the most recent fiscal year for which such 
data are available. Areas that have fallen below either
or both of the required TGA thresholds, but that con-
tinue to be eligible per the RWHAP statute because
HIV Surveillance Supplemental Report 5 Vol. 24, No. 6 
       
       
    
        
       
    
     
     
      
     
         
        
   
 
      
      
   
    
      
        
       
    
        
         
        
       
        
         
         
        
        
        
       
       
         
        
         
        
          
         
         
   
      
         
     
       
        
         
          
          
         
        
        
        
        
       
       
         
          
         
        
           
          
       
        
 
    
     
     
    
      
    
      
      
        
     
         
    
       
       
       
    
    
          
     
        
      
 
      
       
     
     
     
       
     
they must fail both criteria for three consecutive years,
remain designated as TGAs and are presented in the
TGA tables. For FY 2019, there were 28 TGAs.
The geographic boundaries for all jurisdictions that
received Part A funding in FY 2019—both EMAs and 
TGAs—are those metropolitan statistical area (MSA)
boundaries determined by the Office of Management
and Budget (OMB) for use in federal statistical activi-
ties that were in effect when they were initially funded 
under Part A [1–3]. For all newly eligible areas, of
which there were none in FY 2019, the boundaries are
based on current MSA boundary definitions deter-
mined by OMB [1–3]. 
Minority AIDS Initiative (MAI) formula funds for
Part A are awarded based on the reported number of
minority persons living with diagnosed HIV infection,
non-AIDS and infection ever classified as AIDS
reported through the end of the most recent calendar
year as confirmed by the Director of CDC. Data for
MAI formula funds are not included in this report.
RWHAP PART B FUNDING
RWHAP Part B and AIDS Drug Assistance Program
(ADAP) funds are awarded via 3 separate grant award
processes: the RWHAP Part B HIV Care Program
award, the RWHAP Part B Supplemental Grant Pro-
gram award, and the RWHAP Part B ADAP Emer-
gency Relief Fund (ERF) award. The RWHAP Part B
HIV Care Program award has a 5-year project period
and is determined by a legislatively mandated funding
formula process. The award includes the following 5
components: Part B Base award, ADAP Base award,
ADAP Supplemental award (for eligible states that
choose to apply), Emerging Communities award (for
eligible states), and MAI award (for eligible states that
do not decline funding). The RWHAP Part B Supple-
mental grant is a one-year competitive award for states
that demonstrate the need for additional RWHAP Part
B funds. The ADAP ERF grant is also a one-year com-
petitive award. These funds are used to help states pre-
vent, reduce, or eliminate ADAP waiting lists and/or to
implement ADAP-related cost-containment measures. 
RWHAP Part B HIV Care Program Grant 
For the RWHAP Part B Base, ADAP Base, ADAP
Supplemental, Emerging Communities, and MAI
funding formulas, HRSA continues to use cumulative
cases of persons living with diagnosed HIV infection,
non-AIDS and infection ever classified as AIDS in the
state or territory through the end of the most recent cal-
endar year as confirmed by the Director of CDC, as
instructed by the RWHAP statute. The RWHAP Part B
Base formula is a weighted relative distribution that
also takes into account RWHAP Part A funding. Simi-
larly, for recipients applying for MAI formula funds,
awards are based on the reported number of racial/ 
ethnic minorities living with diagnosed HIV infection
non-AIDS and infection ever classified as AIDS
reported through the end of the most recent calendar
year as confirmed by the Director of CDC. Data for
MAI formula funds are not included in this report.
ADAP Supplemental grants are awarded by the same
formula as ADAP Base to states that meet any of the
criteria listed in that section of the Notice of Funding
Opportunity for the purpose of providing medications
or insurance assistance for persons living with HIV
infection.
RWHAP Part B Emerging Communities eligibility 
is determined based on the number of persons living 
with HIV infection ever classified as AIDS in that
jurisdiction. Emerging communities are defined as
metropolitan areas for which there have been at least
500 but fewer than 1,000 AIDS cases reported to and 
confirmed by the Director of CDC during the most
recent 5 calendar years for which such data are avail-
able. An area will remain an EC unless it fails to meet
both of the following requirements for 3 consecutive
fiscal years: (a) a cumulative total of at least 500 but
fewer than 1,000 cases of AIDS reported to and con-
firmed by the Director of CDC during the most recent
period of 5 calendar years for which such data are
available, and (b) a cumulative total of 750 or more
persons living with HIV infection ever classified as
AIDS reported to and confirmed by the Director of
CDC as of December 31 of the most recent year for
which such data are available. As with EMAs and 
TGAs, the geographic boundaries for ECs are those
that were determined by OMB and that were in effect
when initially funded.
RWHAP Part B Supplemental and ADAP
ERF Grants 
RWHAP Part B Supplemental and ADAP ERF grants
are awarded to states demonstrating the severity of the
burden of HIV infection and the need for additional
federal assistance. The funds are intended to supple-
ment the services otherwise provided by the state. All
submitted applications for RWHAP Part B Supple-
HIV Surveillance Supplemental Report 6 Vol. 24, No. 6 
       
      
   
    
  
     
       
   
       
      
      
       
      
    
       
       
   
     
      
      
      
    
 
mental and ADAP ERF competitive grants are
reviewed and ranked by an external objective review
committee; the highest-ranked applications receive
consideration for award within available funding 
ranges. States and territories applying for RWHAP
Part B Supplemental funds must demonstrate that sup-
plemental funding is necessary to provide comprehen-
sive HIV care and treatment services for persons living 
with HIV in the state or territory, and provide quanti-
fiable data on HIV epidemiology, comorbidities, cost
of care, the service needs of emerging populations,
unmet need for core medical services, and unique ser-
vice delivery challenges. States and territories apply-
ing for RWHAP ADAP ERF funds must demonstrate
the need for funding to prevent, reduce, or eliminate a
waiting list, including through “cost-cutting” and/or
“cost-saving” measures, or that need additional fund-
ing for a current or projected increase in treatment
needs aligned with ending the HIV epidemic or other
unanticipated increases in the number of clients in the
program who have newly diagnosed HIV infection or
have reengaged in care. 
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Technical Notes 
In October 2009, Congress enacted amendments to 
the Ryan White HIV/AIDS Program (RWHAP) legis-
lation. The RWHAP legislation specifies the use of
surveillance data on persons living with diagnosed 
HIV infection non-AIDS and infection ever classified 
as AIDS to determine formula funding for RWHAP
Parts A and B HIV care and services programs.
RWHAP authorizes the Centers for Disease Control
and Prevention (CDC) to provide HIV infection non-
AIDS and AIDS case surveillance data to the Health 
Resources and Services Administration (HRSA) for
use in their funding formula for all jurisdictions.
As of December 2017, CDC was not accepting HIV
case data from the Marshall Islands and the Federated 
States of Micronesia, as their surveillance systems had 
not yet been certified. However, in the event that
another jurisdiction reported cases that were diag-
nosed in either the Marshall Islands or the Federated 
States of Micronesia, the cases would be reflected in 
the data that CDC sends annually to HRSA. 
Data re-release agreements between CDC and state/ 
local HIV surveillance programs require certain levels
of cell suppression at the state and county level in 
order to ensure confidentiality of personally identifi-
able information. 
DATA REQUIREMENTS AND DEFINITIONS 
Case counts in all tables are presented by residence at
earliest HIV diagnosis for persons with diagnosed HIV
infection non-AIDS and residence at earliest AIDS
diagnosis for persons with infection ever classified as
AIDS. Data are presented by date of report rather than
date of diagnosis (e.g., reported AIDS cases in the last
5 years). Boundaries for eligible metropolitan areas
(EMAs) and transitional grant areas (TGAs) that
became eligible prior to FY 2007 are based on the
Office of Management and Budget (OMB) metropoli-
tan statistical area (MSA) delineations that were in
effect for such areas for FY 1994 (additional informa-
tion on historical delineations is available at
http://www.census.gov/geographies/reference-files/ 
time-series/demo/metro-micro/historical-delineation-
files.html). Boundaries for EMAs, TGAs, and emerg-
ing communities (ECs) that became eligible after 2006
are determined using applicable OMB definitions
based on the year of first eligibility. 
Reported persons living with diagnosed HIV infec-
tion non-AIDS or infection ever classified as AIDS are
defined as persons reported as “alive” at last update.
HIV infection non-AIDS cases and AIDS case
data reported from CDC met the CDC surveillance
case definitions published in the 2008 and 2014 
revised surveillance case definitions for HIV infec-
tion among adults, adolescents, and children <18 
months and for HIV infection and AIDS among chil-
dren aged 18 months to <13 years [4, 5]. 
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Table 1. Reported AIDS cases and persons reported living with diagnosed HIV infection ever
classified as AIDS, by area of residence, 2013–2017, and as of December 2017—eligible
metropolitan areas and transitional grant areas for the Ryan White HIV/AIDS Program
Reported AIDS cases 
2013–2017 
Persons reported living with
diagnosed HIV infection ever
classified as AIDS (as of
December 2017) 
Area of residence No. No. 
Eligible metropolitan areas (EMAs) 
Atlanta–Sandy Springs–Marietta, Georgia 5,145 16,687 
Baltimore, Maryland 2,080 10,237 
Boston–Brockton–Nashua, Massachusetts–New Hampshire 1,816 10,031 
Chicago, Illinois 3,422 16,430 
Dallas, Texas 2,643 10,972 
Detroit, Michigan 1,399 5,697 
Fort Lauderdale, Florida 1,861 9,471 
Houston, Texas 3,370 14,822 
Los Angeles–Long Beach, California 4,543 27,978 
Miami, Florida 2,723 14,612 
Nassau–Suffolk, New York 680 3,568 
New Haven–Bridgeport–Danbury–Waterbury, Connecticut 461 3,979 
New Orleans, Louisiana 989 4,610 
New York, New York 7,474 61,852 
Newark, New Jersey 1,227 7,111 
Orlando, Florida 1,571 6,002 
Philadelphia, Pennsylvania–New Jersey 2,211 13,981 
Phoenix–Mesa, Arizona 1,192 5,239 
San Diego, California 1,123 7,418 
San Francisco, California 967 10,820 
San Juan–Bayamon, Puerto Rico 1,105 6,290 
Tampa–St. Petersburg–Clearwater, Florida 1,628 6,519 
Washington, DC–Maryland–Virginia–West Virginia 3,553 18,493 
West Palm Beach–Boca Raton, Florida 909 5,006 
Transitional grant areas (TGAs) 
Austin–San Marcos, Texas 
Baton Rouge, Louisiana 
Bergen–Passaic, New Jersey 
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Table 1. Reported AIDS cases and persons reported living with diagnosed HIV infection ever
classified as AIDS, by area of residence, 2013–2017, and as of December 2017—eligible
metropolitan areas and transitional grant areas for the Ryan White HIV/AIDS Program (cont) 
Persons reported living with
diagnosed HIV infection ever
Reported AIDS cases classified as AIDS (as of
2013–2017 December 2017) 
Area of residence No. No. 
Kansas City, Missouri–Kansas 480 2,825 
Las Vegas, Nevada–Arizona 1,017 3,651 
Memphis, Tennessee–Mississippi–Arkansas 1,019 3,557 
Middlesex–Somerset–Hunterdon, New Jersey 300 1,683 
Minneapolis–St. Paul, Minnesota–Wisconsin 624 3,175 
Nashville–Davidson–Murfreesboro, Tennessee 493 2,297 
Norfolk–Virginia Beach–Newport News, Virginia 820 2,732 
Oakland, California 818 5,141 
Orange County, California 652 4,054 
Portland–Vancouver, Oregon–Washington 479 2,791 
Riverside–San Bernardino, California 1,207 5,375 
Sacramento, California 482 2,124 
St. Louis, Missouri–Illinois 726 3,656 
San Antonio, Texas 803 3,342 
San Jose, California 305 2,343 
Seattle–Bellevue–Everett, Washington 682 4,576 
Note. See Commentary for definition of eligible metropolitan areas (EMAs) and transitional grant areas (TGAs). 
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Table 2. Reported AIDS cases and persons reported living with diagnosed HIV infection ever
classified as AIDS, by area of residence, 2013–2017, and as of December 2017—emerging 




Reported AIDS cases 
2013–2017 
classified as AIDS (as of
December 2017) 
Emerging communities (ECs) No. No. 
Albany–Schenectady–Troy, New York 176 1,138 
Augusta–Richmond County, Georgia–South Carolina 398 1,149 
Bakersfield, California 198 1,201 
Birmingham–Hoover, Alabama 584 1,592 
Buffalo–Niagara Falls, New York 309 1,262 
Charleston–North Charleston, South Carolina 302 1,359 
Cincinnati–Middletown, Ohio–Kentucky–Indiana 494 2,039 
Columbia, South Carolina 515 2,498 
Jackson, Mississippi 527 1,724 
Lakeland, Florida 304 1,163 
Louisville, Kentucky–Indiana 419 1,667 
Milwaukee–Waukesha–West Allis, Wisconsin 297 1,572 
North Port–Bradenton–Sarasota, Florida* 231 1,071 
Oklahoma City, Oklahoma 390 1,364 
Philadelphia, Pennsylvania–New Jersey–Delaware–Maryland— 270 1,480 
Wilmington Division 
Pittsburgh, Pennsylvania 379 1,818 
Port St. Lucie–Fort Pierce, Florida 234 1,417 
Providence–New Bedford–Fall River, Rhode Island–Massachusetts 238 1,424 
Raleigh–Cary, North Carolina 421 1,803 
Richmond, Virginia 453 2,060 
Rochester, New York 270 1,607 
Note. See Commentary for definition of emerging communities (ECs). 
* This MSA was formerly named Bradenton–Sarasota–Venice, Florida, but the counties delineating the metropolitan statistical area
have not changed.
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Table 3. Reported number of persons living with diagnosed HIV infection non-AIDS, infection ever
classified as AIDS, and total, by area of residence, as of December 2017—United States and 





as AIDS Total 
Area of residence No. No. No. 
Alabama 7,696 5,587 13,283 
Alaska 326 401 727 
Arizona 8,289 7,032 15,321 
Arkansas 3,157 2,612 5,769 
California 57,795 74,217 132,012 
Colorado 6,947 5,334 12,281 
Connecticut 4,000 6,888 10,888 
Delaware 1,279 1,984 3,263 
District of Columbia 6,699 8,469 15,168 
Florida 52,088 59,027 111,115 
Georgia 23,929 24,885 48,814 
Hawaii 1,168 1,478 2,646 
Idaho 503 463 966 
Illinois 18,339 19,330 37,669 
Indiana 5,494 5,438 10,932 
Iowa 1,083 1,328 2,411 
Kansas 1,525 1,666 3,191 
Kentucky 3,454 3,401 6,855 
Louisiana 10,752 11,075 21,827 
Maine 622 653 1,275 
Maryland 15,050 17,505 32,555 
Massachusetts 8,767 11,208 19,975 
Michigan 8,449 8,552 17,001 
Minnesota 4,415 3,668 8,083 
Mississippi 5,148 4,775 9,923 
Missouri 6,331 6,555 12,886 
Montana 206 265 471 
Nebraska 1,004 1,061 2,065 
Nevada 4,647 4,125 8,772 
New Hampshire 596 626 1,222 
New Jersey 18,245 19,466 37,711 
New Mexico 1,380 1,667 3,047 
New York 53,652 75,094 128,746 
North Carolina 17,132 12,590 29,722 
North Dakota 194 144 338 
Ohio 11,796 10,157 21,953 
Oklahoma 3,175 2,801 5,976 
Oregon 2,600 3,563 6,163 
Pennsylvania 15,814 19,340 35,154 
Rhode Island 1,016 1,453 2,469 
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Table 3. Reported number of persons living with diagnosed HIV infection non-AIDS, infection ever
classified as AIDS, and total, by area of residence, as of December 2017—United States and 





as AIDS Total 
Area of residence No. No. No. 
South Carolina 7,932 9,228 17,160 
South Dakota 312 233 545 
Tennessee 8,874 8,147 17,021 
Texas 42,523 45,235 87,758 
Utah 1,421 1,499 2,920 
Vermont 224 288 512 
Virginia 12,465 10,342 22,807 
Washington 5,868 6,834 12,702 
West Virginia 845 940 1,785 
Wisconsin 3,108 2,853 5,961 
Wyoming 152 165 317 
American Samoa 0 1 1 
Federated States of Micronesia* 0 0 0 
Guam 67 45 112 
Marshall Islands* 0 1 1 
Northern Mariana Islands 3 4 7 
Palau 5 4 9 
Puerto Rico 8,461 10,146 18,607 
U.S. Virgin Islands 270 351 621 
Note. The number of cases shown in the Total column was used by the Health Resources and Services Administration in FY 2019
funding calculations. 
* See Technical Notes regarding data reported for these jurisdictions.
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Table 4. Reported number of persons living with diagnosed HIV infection non-AIDS, infection ever
classified as AIDS, and total, by area of residence, as of December 2017—eligible
metropolitan areas and transitional grant areas for the Ryan White HIV/AIDS Program
HIV infection HIV infection ever
non-AIDS classified as AIDS Total 
Area of residence No. No. No. 
Eligible metropolitan areas (EMAs) 
Atlanta–Sandy Springs–Marietta, Georgia 15,407 16,687 32,094 
Baltimore, Maryland 8,405 10,237 18,642 
Boston–Brockton–Nashua, Massachusetts–New Hampshire 7,805 10,031 17,836 
Chicago, Illinois 15,642 16,430 32,072 
Dallas, Texas 10,546 10,972 21,518 
Detroit, Michigan 5,436 5,697 11,133 
Fort Lauderdale, Florida 8,865 9,471 18,336 
Houston, Texas 13,368 14,822 28,190 
Los Angeles–Long Beach, California 23,403 27,978 51,381 
Miami, Florida 15,155 14,612 29,767 
Nassau–Suffolk, New York 2,702 3,568 6,270 
New Haven–Bridgeport–Danbury–Waterbury, Connecticut 2,291 3,979 6,270 
New Orleans, Louisiana 4,369 4,610 8,979 
New York, New York 43,306 61,852 105,158 
Newark, New Jersey 6,804 7,111 13,915 
Orlando, Florida 5,956 6,002 11,958 
Philadelphia, Pennsylvania–New Jersey 11,644 13,981 25,625 
Phoenix–Mesa, Arizona 6,453 5,239 11,692 
San Diego, California 6,362 7,418 13,780 
San Francisco, California 7,119 10,820 17,939 
San Juan–Bayamon, Puerto Rico 5,584 6,290 11,874 
Tampa–St. Petersburg–Clearwater, Florida 5,507 6,519 12,026 
Washington, DC–Maryland–Virginia–West Virginia 16,405 18,853 34,898 
West Palm Beach–Boca Raton, Florida 
Transitional grant areas (TGAs) 
3,394 5,006 8,400 
Austin–San Marcos, Texas 2,926 3,174 6,100 
Baton Rouge, Louisiana 2,527 2,751 5,278 
Bergen–Passaic, New Jersey 2,147 2,472 4,619 
Charlotte–Gastonia–Concord, North Carolina–South Carolina 4,395 3,034 7,429 
Cleveland–Lorain–Elyria, Ohio 3,018 2,618 5,636 
Columbus, Ohio 3,247 2,468 5,715 
Denver, Colorado 5,386 4,013 9,399 
Fort Worth–Arlington, Texas 2,793 2,797 5,590 
Hartford, Connecticut 1,318 2,313 3,631 
Indianapolis, Indiana 2,685 2,651 5,336 
Jacksonville, Florida 3,115 3,845 6,960 
Jersey City, New Jersey 2,743 2,935 5,678 
Kansas City, Missouri–Kansas 2,333 2,825 5,158 
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Table 4. Reported number of persons living with diagnosed HIV infection non-AIDS, infection ever
classified as AIDS, and total, by area of residence, as of December 2017—eligible
metropolitan areas and transitional grant areas for the Ryan White HIV/AIDS Program (cont) 
HIV infection HIV infection ever
non-AIDS classified as AIDS Total 
Area of residence No. No. No. 
Memphis, Tennessee–Mississippi–Arkansas 4,174 3,557 7,731 
Middlesex–Somerset–Hunterdon, New Jersey 1,526 1,683 3,209 
Minneapolis–St. Paul, Minnesota–Wisconsin 3,912 3,175 7,087 
Nashville–Davidson–Murfreesboro, Tennessee 2,538 2,297 4,835 
Norfolk–Virginia Beach–Newport News, Virginia 4,067 2,732 6,799 
Oakland, California 3,317 5,141 8,458 
Orange County, California 3,584 4,054 7,638 
Portland–Vancouver, Oregon–Washington 2,203 2,791 4,994 
Riverside–San Bernardino, California 4,220 5,375 9,595 
Sacramento, California 2,025 2,124 4,149 
St. Louis, Missouri–Illinois 3,222 3,342 6,564 
San Antonio, Texas 3,222 3,342 6,564 
San Jose, California 1,382 2,343 3,725 
Las Vegas, Nevada–Arizona 4,129 3,651 7,780 
Seattle–Bellevue–Everett, Washington 4,050 4,576 8,626 
Note. See Commentary for definition of eligible metropolitan areas (EMAs) and transitional grant areas (TGAs). 
The number of cases shown in the Total column was used by the Health Resources and Services Administration in FY 2019 funding
calculations. 
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Table 5. Reported number of persons living with diagnosed HIV infection non-AIDS, infection ever
classified as AIDS, and total, by area of residence, as of December 2017—emerging 
communities for the Ryan White HIV/AIDS Program
HIV infection HIV infection ever
non-AIDS classified as AIDS Total 
Emerging communities (ECs) No. No. No. 
Albany–Schenectady–Troy, New York 926 1,138 2,064 
Augusta–Richmond County, Georgia–South Carolina 1,007 1,149 2,156 
Bakersfield, California 931 1,201 2,132 
Birmingham–Hoover, Alabama 2,424 1,592 4,016 
Buffalo–Niagara Falls, New York 1,227 1,262 2,489 
Charleston–North Charleston, South Carolina 1,286 1,359 2,645 
Cincinnati–Middletown, Ohio–Kentucky–Indiana 2,257 2,039 4,296 
Columbia, South Carolina 2,019 2,498 4,517 
Jackson, Mississippi 1,849 1,724 3,573 
Lakeland, Florida 883 1,163 2,046 
Louisville, Kentucky–Indiana 1,865 1,667 3,532 
Milwaukee–Waukesha–West Allis, Wisconsin 1,735 1,572 3,307 
North Port–Bradenton–Sarasota, Florida* 816 1,071 1,887 
Oklahoma City, Oklahoma 1,568 1,364 2,932 
Philadelphia, Pennsylvania–New Jersey–Delaware–Maryland— 960 1,480 2,440 
Wilmington Division 
Pittsburgh, Pennsylvania 1,671 1,818 3,489 
Port St. Lucie–Fort Pierce, Florida 648 1,417 2,065 
Providence–New Bedford–Fall River, Rhode Island– 
Massachusetts 
993 1,424 2,417 
Raleigh–Cary, North Carolina 2,070 1,803 3,873 
Richmond, Virginia 2,645 2,060 4,705 
Rochester, New York 1,303 1,607 2,910 
Note. See Commentary for definition of emerging communities (ECs). 
The number of cases shown in the Total column was used by the Health Resources and Services Administration in FY 2019 funding
calculations. 
* This MSA was formerly named Bradenton–Sarasota–Venice, Florida, but the counties delineating the metropolitan statistical area
have not changed.
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